Stockpolly
Search
SER · AMEX · Biotechnology

Serina Therapeutics (SER)

Develops long-acting drug conjugates through its POZ polymer platform.

$2.65
Pre-market−0.05 (−1.85%)
At close$2.70(+8.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue30000000000
Cost of revenue00022004300
Gross profit300−2−200−4−300
32433663367
Research & development11222334334
21232333333
Selling & marketing00000000000
General & administrative21231333333
Other expenses000−2−100−4−300
Operating income0−2−4−5−6−6−6−6−6−6−7
1−139731−123−10
Interest expense00000000000
Other non-operating income−113−9−7−3−11−2−311
Income before tax1−1551−3−5−6−5−3−7−6
Income tax expense00000000000
Net income from continuing operations1−1551−3−5−6−5−3−7−6
Net income1−1551−3−5−6−5−3−7−6
EPS, basic$0.44−$5.38$0.61$0.16−$0.31−$0.49−$0.64−$0.44−$0.31−$0.58−$0.55
EPS, diluted$0.44−$5.38$0.51$0.13−$0.25−$0.49−$0.64−$0.44−$0.31−$0.58−$0.55
Weighted average shares, basic13999101010101216
Weighted average shares, diluted13101111101010101216
EBITDA1−1551−3−5−6−5−3−7−7
Depreciation & amortization00000000000
EBIT1−1551−3−5−6−5−3−7−7